Sab Biotherapeutics — Efficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase 2a, Randomized, Double-Blind Trial in H1N1 Challenged Adults

12 slides

Sab Biotherapeutics · Health & Biotech · 2022

About this deck

Explore the presentation slide by slide for its financial analysis, transaction details, and investor communications.

Read moreRead less
Company
Sab Biotherapeutics
Industry
Health & Biotech
Year
2022
Slides
12
Company
Sab Biotherapeutics
Industry
Health & Biotech
Year
2022
Slides
12
Sab Biotherapeutics — Efficacy and Safety of SAB-176, a Novel Anti-Type A and B Influenza Immunotherapeutic: A Phase 2a, Randomized, Double-Blind Trial in H1N1 Challenged Adults Investment Banking Pitch Deck | Banker Decks